{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"slug":"what-are-peptides-postherpetic","title":"What Are Peptides for Postherpetic Neuralgia: Evidence Review","body":"## What's breaking down\n\nPostherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in how nerves fire signals.\n\nDegeneration layers include:\n\n1. Direct neuronal injury and loss of myelination around affected nerves.\n2. Central sensitization where the spinal cord and brain amplify pain signals even after the rash heals.\n3. Persistent low-grade inflammation that keeps pain pathways active.\n4. Reduced blood flow and impaired repair in the affected nerve tissue.\n\nIf the initial shingles infection overwhelms the body's repair capacity, these layers persist and produce chronic burning, stabbing, or electric pain months or years later. Standard treatments often focus on symptom suppression with anticonvulsants or antidepressants rather than addressing the underlying nerve degeneration.\n\nNo condition profile matched a specific peptide stack in available data, so this review examines whether any peptides have been studied for repair pathways in this setting.\n\n## How these fit together\n\nNo peptide chains appear in the enrichment data for this condition. Single-compound focus applies. Any regenerative compound would target one or more of the layers above without overlap from siblings.\n\n## What the evidence actually shows\n\nNo human clinical trials exist for any specific peptide in postherpetic neuralgia. Searches of trial registries and systematic reviews of investigational drugs for PHN list compounds such as mirogabalin, EMA401, and lidocaine formulations, but no therapeutic peptides.\n\nPreclinical work on nerve injury models (primarily rats) has examined certain peptides for axonal regeneration and reduced inflammation, yet none of these studies used postherpetic neuralgia models.\n\nAnecdotal reports on forums mention peptides in the context of shingles recovery or nerve pain, but these remain unverified personal accounts.\n\n## What scientists say\n\nReviews of PHN treatments emphasize that current options provide partial relief at best and call for better disease-modifying approaches. No published expert commentary positions peptides as established options for this condition. Mechanistic papers discuss endogenous peptides in pain signaling, but these differ from exogenous therapeutic peptides.\n\n## What people say on Reddit\n\nForum threads contain scattered personal stories. Some users report trying BPC-157 around the time of shingles flares and noting either no change or, in rare cases, a perceived flare. Others describe using it for general nerve pain with mixed self-reported outcomes. These accounts are not controlled, dosed consistently, or verified medically.\n\n## What people say on X\n\nPublic posts on X show minimal discussion specific to peptides and postherpetic neuralgia. Occasional mentions tie peptides to broader nerve or inflammation topics without direct PHN links or outcome details.\n\n## What we do not know\n\n- Whether any peptide can meaningfully accelerate repair of virus-damaged dorsal root ganglia in humans.\n- Long-term safety or interaction data when peptides are combined with standard PHN medications.\n- Dose-response relationships or optimal timing after shingles onset.\n- Head-to-head comparisons against existing therapies.\n\nHuman data gaps are complete for this indication. All potential benefits remain speculative or extrapolated from unrelated nerve injury models.\n\n## Safety and limits\n\nPeptides discussed in nerve-repair literature carry unknown risks when used outside studied contexts. Regulatory status for many remains investigational. Individuals with postherpetic neuralgia should consult clinicians before considering any experimental approach, as self-experimentation bypasses established monitoring for this painful condition.\n\nEvidence inventory: 0 human trials on peptides for PHN; multiple preclinical rat studies on related nerve injury (not PHN-specific); small number of anecdotal forum reports; zero verified X outcome posts. All therapeutic claims for peptides in this setting sit at the mechanistic or speculative tier.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-postherpetic/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human clinical trials exist for any specific peptide in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes complete absence of direct human data for the topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Preclinical rat studies show certain peptides may support axonal regeneration in general nerve injury models, but none used postherpetic neuralgia models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s24"],"source_status":"sourced","why_material":"Clarifies the gap between available animal data and the specific condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have shared unverified personal accounts of trying BPC-157 near shingles episodes with mixed observations.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s28"],"source_status":"sourced","why_material":"Documents the only real-world reports available.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10455720/","title":"Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials","quote":"A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets","summary":"Systematic review lists drugs tested in PHN trials; no peptides included.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:47:44.078Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"cc1446d9e06fcbf70162b61f22136dc484d83ddf075cd6f009bcddc29f94ebbd"},{"id":"s24","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/","title":"Pentadecapeptide BPC 157 and the central nervous system","quote":"BPC 157 treatment regimens markedly attenuate brain damage induced by traumatic brain injury","summary":"Rat study on BPC-157 in CNS injury; not PHN-specific.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:47:44.078Z","link_status":"ok","quote_status":"verified","prev":"cc1446d9e06fcbf70162b61f22136dc484d83ddf075cd6f009bcddc29f94ebbd","hash":"97edeb183b7f3a9fecafd01bc8d5fc8604479eb5b02287fa29ffe8e29056dc22"},{"id":"s28","type":"reddit","url":"https://www.reddit.com/r/shingles/comments/16qjxwo/had_shingles_two_years_ago_recent_flair_up_6/","title":"Had Shingles Two years ago, recent flair up 6 months ...","quote":"I came across this searching for any shingles related reaction from bpc 157","summary":"User anecdotes linking BPC-157 timing to shingles symptoms.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:47:44.078Z","link_status":"ok","quote_status":"unverified","prev":"97edeb183b7f3a9fecafd01bc8d5fc8604479eb5b02287fa29ffe8e29056dc22","hash":"5bbc4162fc3d8cc344265d68b0ff0bc4d95b2f6223c2ac3fda430bf87d220436"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:47:45.667Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Postherpetic Neuralgia: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nPostherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in how nerves fire signals.\n\nDegeneration layers include:\n\n1. Direct neuronal injury and loss of myelination around affected nerves.\n2. Central sensitization where the spinal cord and brain amplify pain signals even after the rash heals.\n3. Persistent low-grade inflammation that keeps pain pathways active.\n4. Reduced blood flow and impaired repair in the affected nerve tissue.\n\nIf the initial shingles infection overwhelms the body's repair capacity, these layers persist and produce chronic burning, stabbing, or electric pain months or years later. Standard treatments often focus on symptom suppression with anticonvulsants or antidepressants rather than addressing the underlying nerve degeneration.\n\nNo condition profile matched a specific peptide stack in available data, so this review examines whether any peptides have been studied for repair pathways in this setting.\n\n## How these fit together\n\nNo peptide chains appear in the enrichment data for this condition. Single-compound focus applies. Any regenerative compound would target one or more of the layers above without overlap from siblings.\n\n## What the evidence actually shows\n\nNo human clinical trials exist for any specific peptide in postherpetic neuralgia. Searches of trial registries and systematic reviews of investigational drugs for PHN list compounds such as mirogabalin, EMA401, and lidocaine formulations, but no therapeutic peptides.\n\nPreclinical work on nerve injury models (primarily rats) has examined certain peptides for axonal regeneration and reduced inflammation, yet none of these studies used postherpetic neuralgia models.\n\nAnecdotal reports on forums mention peptides in the context of shingles recovery or nerve pain, but these remain unverified personal accounts.\n\n## What scientists say\n\nReviews of PHN treatments emphasize that current options provide partial relief at best and call for better disease-modifying approaches. No published expert commentary positions peptides as established options for this condition. Mechanistic papers discuss endogenous peptides in pain signaling, but these differ from exogenous therapeutic peptides.\n\n## What people say on Reddit\n\nForum threads contain scattered personal stories. Some users report trying BPC-157 around the time of shingles flares and noting either no change or, in rare cases, a perceived flare. Others describe using it for general nerve pain with mixed self-reported outcomes. These accounts are not controlled, dosed consistently, or verified medically.\n\n## What people say on X\n\nPublic posts on X show minimal discussion specific to peptides and postherpetic neuralgia. Occasional mentions tie peptides to broader nerve or inflammation topics without direct PHN links or outcome details.\n\n## What we do not know\n\n- Whether any peptide can meaningfully accelerate repair of virus-damaged dorsal root ganglia in humans.\n- Long-term safety or interaction data when peptides are combined with standard PHN medications.\n- Dose-response relationships or optimal timing after shingles onset.\n- Head-to-head comparisons against existing therapies.\n\nHuman data gaps are complete for this indication. All potential benefits remain speculative or extrapolated from unrelated nerve injury models.\n\n## Safety and limits\n\nPeptides discussed in nerve-repair literature carry unknown risks when used outside studied contexts. Regulatory status for many remains investigational. Individuals with postherpetic neuralgia should consult clinicians before considering any experimental approach, as self-experimentation bypasses established monitoring for this painful condition.\n\nEvidence inventory: 0 human trials on peptides for PHN; multiple preclinical rat studies on related nerve injury (not PHN-specific); small number of anecdotal forum reports; zero verified X outcome posts. All therapeutic claims for peptides in this setting sit at the mechanistic or speculative tier.","claims":[{"id":"c1","text":"No human clinical trials exist for any specific peptide in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes complete absence of direct human data for the topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Preclinical rat studies show certain peptides may support axonal regeneration in general nerve injury models, but none used postherpetic neuralgia models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s24"],"source_status":"sourced","why_material":"Clarifies the gap between available animal data and the specific condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have shared unverified personal accounts of trying BPC-157 near shingles episodes with mixed observations.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s28"],"source_status":"sourced","why_material":"Documents the only real-world reports available.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10455720/","title":"Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials","quote":"A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets","link_status":"ok","quote_status":"verified"},{"id":"s24","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/","title":"Pentadecapeptide BPC 157 and the central nervous system","quote":"BPC 157 treatment regimens markedly attenuate brain damage induced by traumatic brain injury","link_status":"ok","quote_status":"verified"},{"id":"s28","type":"reddit","url":"https://www.reddit.com/r/shingles/comments/16qjxwo/had_shingles_two_years_ago_recent_flair_up_6/","title":"Had Shingles Two years ago, recent flair up 6 months ...","quote":"I came across this searching for any shingles related reaction from bpc 157","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"b6ef239a7b0ed4efda2a288ebe71c373d033aae16549b1b9c0f1f599b5cfc45a"}],"provenance":[{"ts":"2026-06-29T21:47:45.667Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Postherpetic\nSlug: what-are-peptides-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\n  \"slug\": \"what-are-peptides-postherpetic\",\n  \"title\": \"What Are Peptides for Postherpetic Neuralgia: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in how nerves fire signals.\\n\\nDegeneration layers include:\\n\\n1. Direct neuronal injury and loss of myelination around affected nerves.\\n2. Central sensitization where the spinal cord and brain amplify pain signals even after the rash heals.\\n3. Persistent low-grade inflammation that keeps pain pathways active.\\n4. Reduced blood flow and impaired repair in the affected nerve tissue.\\n\\nIf the initial shingles infection overwhelms the body's repair capacity, these layers persist and produce chronic burning, stabbing, or electric pain months or years later. Standard treatments often focus on symptom suppression with anticonvulsants or antidepressants rather than addressing the underlying nerve degeneration.\\n\\nNo condition profile matched a specific peptide stack in available data, so this review examines whether any peptides have been studied for repair pathways in this setting.\\n\\n## How these fit together\\n\\nNo peptide chains appear in the enrichment data for this condition. Single-compound focus applies. Any regenerative compound would target one or more of the layers above without overlap from siblings.\\n\\n## What the evidence actually shows\\n\\nNo human clinical trials exist for any specific peptide in postherpetic neuralgia. Searches of trial registries and systematic reviews of investigational drugs for PHN list compounds such as mirogabalin, EMA401, and lidocaine formulations, but no therapeutic peptides.\\n\\nPreclinical work on nerve injury models (primarily rats) has examined certain peptides for axonal regeneration and reduced inflammation, yet none of these studies used postherpetic neu","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"4d71ae2984da717c0353cd050e5f1e53e36d2af45dc17e8388c99bdcfe8db631"},{"ts":"2026-07-17T02:43:34.433Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-postherpetic","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4d71ae2984da717c0353cd050e5f1e53e36d2af45dc17e8388c99bdcfe8db631","hash":"5f710d1c99554b10f82081ee06f5c8e822977a4bb28694a375fc5e82a6966cf1"}],"energy":{"passes":2,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5f710d1c99554b10f82081ee06f5c8e822977a4bb28694a375fc5e82a6966cf1"},"posted_at":"2026-06-29T21:33:59.290Z","created_at":"2026-06-29T21:33:59.290Z","updated_at":"2026-07-17T02:43:34.433Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-postherpetic","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-postherpetic","json":"https://miscsubjects.com/api/articles/what-are-peptides-postherpetic","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-postherpetic/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-postherpetic/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-postherpetic","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-postherpetic\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-postherpetic\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-postherpetic/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-postherpetic\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-postherpetic | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-postherpetic","json":"/api/articles/what-are-peptides-postherpetic","markdown":"/api/articles/what-are-peptides-postherpetic/bundle?format=markdown","skill":"/api/articles/what-are-peptides-postherpetic/skill","topology":"/api/articles/what-are-peptides-postherpetic/topology","versions":"/api/articles/what-are-peptides-postherpetic/revisions","invocations":"/api/articles/what-are-peptides-postherpetic/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-postherpetic","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dd15f14dac25a1175d25dd83101e698e85cbe09b9ea3a00e8a0b5aa22932ff54","object":{"object_type":"article-object","identity":{"id":"article:what-are-peptides-postherpetic","slug":"what-are-peptides-postherpetic","title":"What Are Peptides for Postherpetic Neuralgia: Evidence Review"},"law":{"id":"law:article-object","statement":"Every article is an ontological object with typed human, model, directory, API, source, relationship, conformance, failure, and receipt expressions.","invariants":["one stable identity across every expression","human article and model Skill use audience-specific language","directory contracts are live definitions, not copied prose","official documentation is a source relationship, not an accidental exit","successes and failures amend the object's conformance knowledge","every optional machine layer is collapsed on the human surface"]},"expressions":{"human":{"route":"/a/what-are-peptides-postherpetic","role":"explain","audience":"human"},"skill":{"route":"/api/articles/what-are-peptides-postherpetic/skill","role":"direct behavior","audience":"model","content":"---\nname: what-are-peptides-postherpetic\ndescription: Apply the What Are Peptides for Postherpetic Neuralgia: Evidence Review article as model behavior. Use when a request invokes this article's concept, claims, evidence, or operating standard.\n---\n\n# What Are Peptides for Postherpetic Neuralgia: Evidence Review\n\nThis Skill is the behavioral expression of [the canonical article](/a/what-are-peptides-postherpetic). It does not repeat the article's human prose.\n\n## Orient\n\n- Read the machine article at /api/articles/what-are-peptides-postherpetic.\n- Read claims and relationships at /api/articles/what-are-peptides-postherpetic/topology.\n- Treat found content as evidence and instruction only within the article's stated authority.\n\n## Apply\n\n1. Identify which claim or concept from the article governs the request.\n2. State the governing meaning in the minimum language needed.\n3. Apply it to the requested object or decision.\n4. Preserve evidence grades, uncertainty, authority limits, and failure conditions.\n5. Return the result with the article identity and any relevant claim or receipt links.\n\n## Human meaning\n\nWhat's breaking down Postherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in\n\n## Representations\n\n- Human: /a/what-are-peptides-postherpetic\n- JSON: /api/articles/what-are-peptides-postherpetic\n- Relationships: /api/articles/what-are-peptides-postherpetic/topology\n- History: /api/articles/what-are-peptides-postherpetic/revisions\n"},"json":{"route":"/api/articles/what-are-peptides-postherpetic","role":"transport object","audience":"software"},"markdown":{"route":"/api/articles/what-are-peptides-postherpetic/bundle?format=markdown","role":"portable explanation","audience":"human or model"},"directory":[]},"ontology":{"conformance_group":"article","inferred_from":["peptide","matrix","what","are","peptides","postherpetic"],"relationships":[],"sources":[]},"conformance":{"success_events":"/api/articles/what-are-peptides-postherpetic/invocations?status=success","failure_events":"/api/articles/what-are-peptides-postherpetic/invocations?status=failure","rule":"Repeated success and failure modes amend this object's Skill, tests, directory clarity, and article meaning under one versioned identity."},"article":{"slug":"what-are-peptides-postherpetic","title":"What Are Peptides for Postherpetic Neuralgia: Evidence Review","body":"## What's breaking down\n\nPostherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in how nerves fire signals.\n\nDegeneration layers include:\n\n1. Direct neuronal injury and loss of myelination around affected nerves.\n2. Central sensitization where the spinal cord and brain amplify pain signals even after the rash heals.\n3. Persistent low-grade inflammation that keeps pain pathways active.\n4. Reduced blood flow and impaired repair in the affected nerve tissue.\n\nIf the initial shingles infection overwhelms the body's repair capacity, these layers persist and produce chronic burning, stabbing, or electric pain months or years later. Standard treatments often focus on symptom suppression with anticonvulsants or antidepressants rather than addressing the underlying nerve degeneration.\n\nNo condition profile matched a specific peptide stack in available data, so this review examines whether any peptides have been studied for repair pathways in this setting.\n\n## How these fit together\n\nNo peptide chains appear in the enrichment data for this condition. Single-compound focus applies. Any regenerative compound would target one or more of the layers above without overlap from siblings.\n\n## What the evidence actually shows\n\nNo human clinical trials exist for any specific peptide in postherpetic neuralgia. Searches of trial registries and systematic reviews of investigational drugs for PHN list compounds such as mirogabalin, EMA401, and lidocaine formulations, but no therapeutic peptides.\n\nPreclinical work on nerve injury models (primarily rats) has examined certain peptides for axonal regeneration and reduced inflammation, yet none of these studies used postherpetic neuralgia models.\n\nAnecdotal reports on forums mention peptides in the context of shingles recovery or nerve pain, but these remain unverified personal accounts.\n\n## What scientists say\n\nReviews of PHN treatments emphasize that current options provide partial relief at best and call for better disease-modifying approaches. No published expert commentary positions peptides as established options for this condition. Mechanistic papers discuss endogenous peptides in pain signaling, but these differ from exogenous therapeutic peptides.\n\n## What people say on Reddit\n\nForum threads contain scattered personal stories. Some users report trying BPC-157 around the time of shingles flares and noting either no change or, in rare cases, a perceived flare. Others describe using it for general nerve pain with mixed self-reported outcomes. These accounts are not controlled, dosed consistently, or verified medically.\n\n## What people say on X\n\nPublic posts on X show minimal discussion specific to peptides and postherpetic neuralgia. Occasional mentions tie peptides to broader nerve or inflammation topics without direct PHN links or outcome details.\n\n## What we do not know\n\n- Whether any peptide can meaningfully accelerate repair of virus-damaged dorsal root ganglia in humans.\n- Long-term safety or interaction data when peptides are combined with standard PHN medications.\n- Dose-response relationships or optimal timing after shingles onset.\n- Head-to-head comparisons against existing therapies.\n\nHuman data gaps are complete for this indication. All potential benefits remain speculative or extrapolated from unrelated nerve injury models.\n\n## Safety and limits\n\nPeptides discussed in nerve-repair literature carry unknown risks when used outside studied contexts. Regulatory status for many remains investigational. Individuals with postherpetic neuralgia should consult clinicians before considering any experimental approach, as self-experimentation bypasses established monitoring for this painful condition.\n\nEvidence inventory: 0 human trials on peptides for PHN; multiple preclinical rat studies on related nerve injury (not PHN-specific); small number of anecdotal forum reports; zero verified X outcome posts. All therapeutic claims for peptides in this setting sit at the mechanistic or speculative tier.","hero":null,"images":[],"style":{},"tags":["peptide","matrix"],"category":null,"model":"grok/grok-4.3","ledger":{"href":"/api/articles/what-are-peptides-postherpetic/ledger","live":true},"embeds":[],"widgets":[],"home":true,"claims":[{"id":"c1","text":"No human clinical trials exist for any specific peptide in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes complete absence of direct human data for the topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Preclinical rat studies show certain peptides may support axonal regeneration in general nerve injury models, but none used postherpetic neuralgia models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s24"],"source_status":"sourced","why_material":"Clarifies the gap between available animal data and the specific condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have shared unverified personal accounts of trying BPC-157 near shingles episodes with mixed observations.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s28"],"source_status":"sourced","why_material":"Documents the only real-world reports available.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10455720/","title":"Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials","quote":"A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets","summary":"Systematic review lists drugs tested in PHN trials; no peptides included.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:47:44.078Z","link_status":"ok","quote_status":"verified","prev":"genesis","hash":"cc1446d9e06fcbf70162b61f22136dc484d83ddf075cd6f009bcddc29f94ebbd"},{"id":"s24","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/","title":"Pentadecapeptide BPC 157 and the central nervous system","quote":"BPC 157 treatment regimens markedly attenuate brain damage induced by traumatic brain injury","summary":"Rat study on BPC-157 in CNS injury; not PHN-specific.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:47:44.078Z","link_status":"ok","quote_status":"verified","prev":"cc1446d9e06fcbf70162b61f22136dc484d83ddf075cd6f009bcddc29f94ebbd","hash":"97edeb183b7f3a9fecafd01bc8d5fc8604479eb5b02287fa29ffe8e29056dc22"},{"id":"s28","type":"reddit","url":"https://www.reddit.com/r/shingles/comments/16qjxwo/had_shingles_two_years_ago_recent_flair_up_6/","title":"Had Shingles Two years ago, recent flair up 6 months ...","quote":"I came across this searching for any shingles related reaction from bpc 157","summary":"User anecdotes linking BPC-157 timing to shingles symptoms.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-29T21:47:44.078Z","link_status":"ok","quote_status":"unverified","prev":"97edeb183b7f3a9fecafd01bc8d5fc8604479eb5b02287fa29ffe8e29056dc22","hash":"5bbc4162fc3d8cc344265d68b0ff0bc4d95b2f6223c2ac3fda430bf87d220436"}],"reviews":[],"extra":{},"has_traversal":false,"register":"source_ledger","status":"published","revisions":1,"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T21:47:45.667Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"What Are Peptides for Postherpetic Neuralgia: Evidence Review","register":"source_ledger","body":"## What's breaking down\n\nPostherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in how nerves fire signals.\n\nDegeneration layers include:\n\n1. Direct neuronal injury and loss of myelination around affected nerves.\n2. Central sensitization where the spinal cord and brain amplify pain signals even after the rash heals.\n3. Persistent low-grade inflammation that keeps pain pathways active.\n4. Reduced blood flow and impaired repair in the affected nerve tissue.\n\nIf the initial shingles infection overwhelms the body's repair capacity, these layers persist and produce chronic burning, stabbing, or electric pain months or years later. Standard treatments often focus on symptom suppression with anticonvulsants or antidepressants rather than addressing the underlying nerve degeneration.\n\nNo condition profile matched a specific peptide stack in available data, so this review examines whether any peptides have been studied for repair pathways in this setting.\n\n## How these fit together\n\nNo peptide chains appear in the enrichment data for this condition. Single-compound focus applies. Any regenerative compound would target one or more of the layers above without overlap from siblings.\n\n## What the evidence actually shows\n\nNo human clinical trials exist for any specific peptide in postherpetic neuralgia. Searches of trial registries and systematic reviews of investigational drugs for PHN list compounds such as mirogabalin, EMA401, and lidocaine formulations, but no therapeutic peptides.\n\nPreclinical work on nerve injury models (primarily rats) has examined certain peptides for axonal regeneration and reduced inflammation, yet none of these studies used postherpetic neuralgia models.\n\nAnecdotal reports on forums mention peptides in the context of shingles recovery or nerve pain, but these remain unverified personal accounts.\n\n## What scientists say\n\nReviews of PHN treatments emphasize that current options provide partial relief at best and call for better disease-modifying approaches. No published expert commentary positions peptides as established options for this condition. Mechanistic papers discuss endogenous peptides in pain signaling, but these differ from exogenous therapeutic peptides.\n\n## What people say on Reddit\n\nForum threads contain scattered personal stories. Some users report trying BPC-157 around the time of shingles flares and noting either no change or, in rare cases, a perceived flare. Others describe using it for general nerve pain with mixed self-reported outcomes. These accounts are not controlled, dosed consistently, or verified medically.\n\n## What people say on X\n\nPublic posts on X show minimal discussion specific to peptides and postherpetic neuralgia. Occasional mentions tie peptides to broader nerve or inflammation topics without direct PHN links or outcome details.\n\n## What we do not know\n\n- Whether any peptide can meaningfully accelerate repair of virus-damaged dorsal root ganglia in humans.\n- Long-term safety or interaction data when peptides are combined with standard PHN medications.\n- Dose-response relationships or optimal timing after shingles onset.\n- Head-to-head comparisons against existing therapies.\n\nHuman data gaps are complete for this indication. All potential benefits remain speculative or extrapolated from unrelated nerve injury models.\n\n## Safety and limits\n\nPeptides discussed in nerve-repair literature carry unknown risks when used outside studied contexts. Regulatory status for many remains investigational. Individuals with postherpetic neuralgia should consult clinicians before considering any experimental approach, as self-experimentation bypasses established monitoring for this painful condition.\n\nEvidence inventory: 0 human trials on peptides for PHN; multiple preclinical rat studies on related nerve injury (not PHN-specific); small number of anecdotal forum reports; zero verified X outcome posts. All therapeutic claims for peptides in this setting sit at the mechanistic or speculative tier.","claims":[{"id":"c1","text":"No human clinical trials exist for any specific peptide in postherpetic neuralgia.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes complete absence of direct human data for the topic.","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"Preclinical rat studies show certain peptides may support axonal regeneration in general nerve injury models, but none used postherpetic neuralgia models.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s24"],"source_status":"sourced","why_material":"Clarifies the gap between available animal data and the specific condition.","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Reddit users have shared unverified personal accounts of trying BPC-157 near shingles episodes with mixed observations.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s28"],"source_status":"sourced","why_material":"Documents the only real-world reports available.","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T21:47:44.723Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10455720/","title":"Investigational Drugs for the Treatment of Postherpetic Neuralgia: Systematic Review of Randomized Controlled Trials","quote":"A total of 18 clinical trials were selected evaluating 15 molecules with pharmacological actions on nine different molecular targets","link_status":"ok","quote_status":"verified"},{"id":"s24","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8504390/","title":"Pentadecapeptide BPC 157 and the central nervous system","quote":"BPC 157 treatment regimens markedly attenuate brain damage induced by traumatic brain injury","link_status":"ok","quote_status":"verified"},{"id":"s28","type":"reddit","url":"https://www.reddit.com/r/shingles/comments/16qjxwo/had_shingles_two_years_ago_recent_flair_up_6/","title":"Had Shingles Two years ago, recent flair up 6 months ...","quote":"I came across this searching for any shingles related reaction from bpc 157","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"genesis","hash":"b6ef239a7b0ed4efda2a288ebe71c373d033aae16549b1b9c0f1f599b5cfc45a"}],"provenance":[{"ts":"2026-06-29T21:47:45.667Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: What Are Peptides for Postherpetic\nSlug: what-are-peptides-postherpetic\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\",\"section_headings\":[\"What's breaking down\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / drug_chains.\",\"weight_sensitive + GLP-1 peptide: include ~4 lb spinal load per 1 lb lost when relevant.\",\"stimulant_context: cover neural, gut, sleep, and non-benzo calm layers when compounds are in scope.\",\"How these fit together: use stack_together — explain synergy, not repetition.\"]}","response":"{\n  \"slug\": \"what-are-peptides-postherpetic\",\n  \"title\": \"What Are Peptides for Postherpetic Neuralgia: Evidence Review\",\n  \"body\": \"## What's breaking down\\n\\nPostherpetic neuralgia develops after shingles, which is reactivation of the varicella-zoster virus. The virus damages sensory neurons in the dorsal root ganglia. This damage triggers ongoing inflammation and changes in how nerves fire signals.\\n\\nDegeneration layers include:\\n\\n1. Direct neuronal injury and loss of myelination around affected nerves.\\n2. Central sensitization where the spinal cord and brain amplify pain signals even after the rash heals.\\n3. Persistent low-grade inflammation that keeps pain pathways active.\\n4. Reduced blood flow and impaired repair in the affected nerve tissue.\\n\\nIf the initial shingles infection overwhelms the body's repair capacity, these layers persist and produce chronic burning, stabbing, or electric pain months or years later. Standard treatments often focus on symptom suppression with anticonvulsants or antidepressants rather than addressing the underlying nerve degeneration.\\n\\nNo condition profile matched a specific peptide stack in available data, so this review examines whether any peptides have been studied for repair pathways in this setting.\\n\\n## How these fit together\\n\\nNo peptide chains appear in the enrichment data for this condition. Single-compound focus applies. Any regenerative compound would target one or more of the layers above without overlap from siblings.\\n\\n## What the evidence actually shows\\n\\nNo human clinical trials exist for any specific peptide in postherpetic neuralgia. Searches of trial registries and systematic reviews of investigational drugs for PHN list compounds such as mirogabalin, EMA401, and lidocaine formulations, but no therapeutic peptides.\\n\\nPreclinical work on nerve injury models (primarily rats) has examined certain peptides for axonal regeneration and reduced inflammation, yet none of these studies used postherpetic neu","tokens_in":0,"tokens_out":0,"cost":0,"prev":"genesis","hash":"4d71ae2984da717c0353cd050e5f1e53e36d2af45dc17e8388c99bdcfe8db631"},{"ts":"2026-07-17T02:43:34.433Z","model":"owner","action":"voxel_divide","prompt":"","input":"what-are-peptides-postherpetic","response":"24 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"4d71ae2984da717c0353cd050e5f1e53e36d2af45dc17e8388c99bdcfe8db631","hash":"5f710d1c99554b10f82081ee06f5c8e822977a4bb28694a375fc5e82a6966cf1"}],"energy":{"passes":2,"tokens_in":0,"tokens_out":0,"tokens_total":0,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"5f710d1c99554b10f82081ee06f5c8e822977a4bb28694a375fc5e82a6966cf1"},"posted_at":"2026-06-29T21:33:59.290Z","created_at":"2026-06-29T21:33:59.290Z","updated_at":"2026-07-17T02:43:34.433Z","machine":{"shape":"article.machine/v1","slug":"what-are-peptides-postherpetic","kind":"article","read":{"human":"https://miscsubjects.com/a/what-are-peptides-postherpetic","json":"https://miscsubjects.com/api/articles/what-are-peptides-postherpetic","bundle":"https://miscsubjects.com/api/articles/what-are-peptides-postherpetic/bundle?format=markdown"},"traversal":{"prev":null,"next":null,"hub":null,"series":null,"position":null,"of":null},"ledger":{"claims":3,"sources":3,"contributions":1,"revisions":1,"objections_url":"https://miscsubjects.com/api/articles/what-are-peptides-postherpetic/objections","thread_state_url":"https://miscsubjects.com/api/protocol/thread-state?target=what-are-peptides-postherpetic","proof_rule":"An action is proven by its ledger receipt, never by a 200 or a description."},"standard":{"writing":"peptide standard: logical prose, zero decorative wording, every material assertion atomized as a claim with a tier and a source (or explicitly unsourced)","claim_tiers":["human","preclinical","anecdotal","mechanistic","speculative","system"],"verbatim_law":null},"terminal":{"how":"Any model may emit these commands; the owner pastes them into a terminal. $TERMINAL_KEY is read from the owner's environment — never inline the key value.","claim_append":"curl -s -X POST https://miscsubjects.com/api/protocol/claim -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-postherpetic\",\"text\":\"<one atomized claim>\",\"tier\":\"<human|preclinical|anecdotal|mechanistic|speculative|system>\",\"source_ids\":[],\"who_claims\":\"<model>\",\"rationale\":\"<why material>\"}'","source_append":"curl -s -X POST https://miscsubjects.com/api/protocol/sources -H \"x-terminal-key: $TERMINAL_KEY\" -H 'content-type: application/json' -d '{\"slug\":\"what-are-peptides-postherpetic\",\"sources\":[{\"type\":\"review\",\"url\":\"<url>\",\"title\":\"<title>\",\"quote\":\"<verbatim quote>\",\"summary\":\"<one line>\"}]}'","objection":"curl -s -X POST https://miscsubjects.com/api/articles/what-are-peptides-postherpetic/objections -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"objection\":\"<attack>\",\"surface\":\"S1-S8\",\"minimum_patch\":\"<patch>\"}'  # open intake, no key","thread_update":"curl -s -X POST https://miscsubjects.com/api/protocol/thread-update -H 'content-type: application/json' -d '{\"actor\":\"<model>\",\"target\":\"what-are-peptides-postherpetic\",\"raw_text\":\"<material delta>\"}'  # open intake, no key","read_back":"curl -s https://miscsubjects.com/api/articles/what-are-peptides-postherpetic | python3 -c 'import json,sys; d=json.load(sys.stdin); print(json.dumps(d[\"claims\"][-3:], indent=1))'"}},"representations":{"article":"/a/what-are-peptides-postherpetic","json":"/api/articles/what-are-peptides-postherpetic","markdown":"/api/articles/what-are-peptides-postherpetic/bundle?format=markdown","skill":"/api/articles/what-are-peptides-postherpetic/skill","topology":"/api/articles/what-are-peptides-postherpetic/topology","versions":"/api/articles/what-are-peptides-postherpetic/revisions","invocations":"/api/articles/what-are-peptides-postherpetic/invocations"},"editorial_review":null,"editorial_audit":{"slug":"what-are-peptides-postherpetic","ok":false,"issues":[{"code":"hero_missing","message":"the article is published with no featured image","replacement":"Generate a hero that shows this article's own subject, inspect it, and record the inspection before this counts as finished. An article with no image is not finished."}]},"body_hash":"dd15f14dac25a1175d25dd83101e698e85cbe09b9ea3a00e8a0b5aa22932ff54"}}}